StemCell Therapy

Latest release from SMI with title Animal Stem Cell Therapy Market Research Report 2019-2026 (by Product Type, End-User / Application and Regions / Countries) provides an in-depth assessment of the Animal Stem Cell Therapy including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. Global Animal Stem Cell Therapy Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released BY SMI. The report presents a complete assessment of the Market covering future trends, current growth factors, attentive opinions, facts, and industry-validated market data forecast until 2026.

Global Animal Stem Cell Therapy Market Segmentations

The segmentation chapter allows readers to understand aspects of the Global Animal Stem Cell Therapy Market such as products/services, available technologies, and applications. These chapters are written in a way that describes years of development and the process that will take place in the next few years. The research report also provides insightful information on new trends that are likely to define the progress of these segments over the next few years.

Download FREE Sample Report with Latest Industry Trends 2019 @ https://www.stratagemmarketinsights.com/sample/11599(**Note: Free Sample Copy Only with TOC, Graph, Charts)

Global Animal Stem Cell Therapy Market and Competitive Analysis

Know your current market situation! Not only an important element for new products but also for current products given the ever-changing market dynamics. The study allows marketers to stay in touch with current consumer trends and segments where they can face a rapid market share drop. Discover who you really compete against in the marketplace, with Market Share Analysis know market position, % market Share and Segmented Revenue of Animal Stem Cell Therapy Market

Segmentation and Targeting

Essential demographic, geographic, psychographic and behavioral information about business segments in the Animal Stem Cell Therapy market is targeted to aid in determining the features company should encompass in order to fit into the business requirements. For the Consumer-based market the study is also classified with Market Maker information in order to better understand who the clients are, their buying behavior and patterns.

*** For the global version, a list of below countries by region can be added as part of customization at minimum cost.North America (United States, Canada & Mexico)Asia-Pacific (Japan, China, India, Australia, etc)Europe (Germany, UK, France, etc)Central & South America (Brazil, Argentina, etc)Middle East & Africa (United Arab Emirates, Saudi Arabia, South Africa, etc)

Animal Stem Cell Therapy Product/Service Development

Knowing how the product/services fit the needs of clients and what changes would require to make the product more attractive is the need of an hour. Useful approaches to focus group by utilizing User Testing and User Experience Research. Demand-side analysis always helps to correlate consumer preferences with innovation.

Marketing Communication and Sales Channel

Understanding marketing effectiveness on a continual basis help determine the potential of advertising and marketing communications and allow us to use best practices to utilize an untapped audience. In order to make marketers make effective strategies and identify why the target market is not giving attention, we ensure the Study is Segmented with appropriate marketing & sales channels to identify potential market size by Revenue and Volume* (if Applicable).

Pricing and Forecast

Pricing/subscription always plays an important role in buying decisions; so we have analyzed pricing to determine how customers or businesses evaluate it not just in relation to other product offerings by competitors but also with immediate substitute products. In addition to future sales Separate Chapters on Cost Analysis, Labor*, production* and Capacity are Covered.

How geography and sales fit together

This study is helpful to all operators who want to identify the exact size of their target audience at a specific geographic location. Animal Stem Cell Therapy Market allows entrepreneurs to determine local markets for business expansion. This study answers the questions below:

1. Where do the requirements come from?2. Where do non-potential customers reside?3. What is the buying behavior of customers in a specific region?4. What is the spending power of the customers in a particular region?

** Enquire for customization in Report @ https://www.stratagemmarketinsights.com/quiry/11599

Having our reviews and subscribing our report will help you solve the subsequent issues:

*Uncertainty about the future: Our research and insights help our customers predict the upcoming revenue pockets and growth areas. This will guide customers to invest their resources.

*Understanding market sentiments: It is very important to have a fair understanding of market sentiment for your strategy. Our insights will help you see every single eye on market sentiment. We maintain this analysis by working with key opinion leaders on the value chain of each industry we track.

*Understanding the most reliable investment center: Our research evaluates investment centers in the market, taking into account future demand, profits, and returns. Clients can focus on the most prestigious investment centers through market research.

*Evaluating potential business partners: Our research and insights help our clients in identifying compatible business partners.

Furthermore, the years considered for the study are as follows:

Historical year 2013-2018Base year 2018Forecast period** 2019 to 2026 [** unless otherwise stated]

More Related Reports ajitk123

See the original post here:
What Will Be The Growth of Animal Stem Cell Therapy Market? Dagoretti News - Dagoretti News

The air is warm and humid, there is an abundance of food, and your friends come and go with their shiny toys. What sounds like a dreamy summer holiday is also the reality of in vitro cell culture experiments, and a golden opportunity for contaminants to intrude. Every person, reagent, and piece of equipment in the laboratory is a potential vehicle for invasive microbes, unwelcome cells and chemical impurities, which can create costly issues in both bench research and manufacturing. Cell culture contamination is a problem on many levels, creating immediate implications for experiments and wider issues for the scientific community.Consequences of cell culture contaminationContaminants can affect all cell characteristics (e.g. growth, metabolism, and morphology) and contribute to unreliable or erroneous experimental results. Cell culture contamination will likely create a need for experiments to be repeated, resulting in frustrating time delays and costly reagent wastage. Data derived from undetected contaminated cultures can end up published in scientific journals, allowing others to build hypotheses from dubious results. The pervasiveness of cross-contaminated and misidentified cell lines is a decades-long issue; in 1967, cell lines thought to be derived from various tissues were shown to be HeLa cells, a human cervical adenocarcinoma cell line.1 However, studies involving these misidentified cell lines continued to feature in hundreds of citations during the early 2000s.2This pattern is a well-acknowledged problem and threatens to undermine scientific integrity. The first published retraction in Nature Methods was due to cell line contamination3, and one conservative estimate of contaminated literature in 2017 found 32,755 articles reporting on research with misidentified cells.4 While many scientists may have been blissfully ignorant in the past, awareness of misidentified cell lines is growing.Deciding how best to deal with this knowledge is not straightforward and has been discussed extensively.4 In the interest of preventing further data contamination, a certificate of authentication of the origin and identity of human cells is now required by the International Journal of Cancer, and encouraged by funding agencies. Others have questioned whether mandatory testing really is the best way forward.3But what should be done about existing contaminated literature? Mass retraction of affected articles may disproportionately punish the careers of a few scientists, and could be a waste of resources containing potentially valuable data. One recently proposed system of self-retraction recommends replacing blame with praise in order to encourage self-correction.5 Post hoc labeling of published articles in the form of an expression of concern allows existing findings to remain accessible, while giving readers a chance to form their own judgement.

Lastly, pathogens carried by cells (either intentionally or accidentally) or in components of the culture medium are potential health hazards, and laboratory-acquired viral infections have been reported.6-8 Indeed, the stakes are higher when cells are to be introduced into patients, highlighting the critical importance of quality control in cell therapies.

While pipetting is a key part of everyday laboratory work, it is also one of the stages most prone to contamination. As sample contamination can affect the reliability of results, it is important to know how it can be avoided, saving both time and money. Download this poster for ten tips to avoiding contamination in pipetting.

Avoid leaving your cultures out of the incubator for extended periods

Label all cultures clearly and unambiguously

Disinfect work surfaces before and after use

Check disinfectants are effective and appropriate choices for the job

Work with only one cell culture at a time

Use separate media and reagents for each individual cell line

Quarantine new cell lines until tested negative for mycoplasma

Avoid overusing and relying on antibiotics

Record how long a cell line has been kept in cultureThe design of the laboratory can also play a role; cabinets should be placed away from through-traffic, doors and air-conditioning inlets.6 Restricting area access to allow only essential laboratory personnel to enter reduces disturbances of airflow around the microbiological safety cabinet.

Water baths, CO2 incubators, shelves and water pans are common culprits and should be cleaned or autoclaved regularly, using a chemical disinfectant where appropriate. Other routes of infection include accidental spillages, contact with non-sterile surfaces, splash-back from pipetting or pouring, microscopic aerosol, and infestation by vertebrates, dust and mites.Research groups isolating stem cells use unique cell properties to filter out undesired cells, explains Dr Mei-Ju Hsu, postdoctoral researcher in stem cell therapy at Leipzig University. Dr Hsu notes that: one of the most important features of mesenchymal stem cells is the attachment and growth on the plastic surfaces without prior coating. This step serves as a good way to eliminate the non-adherent cells (e.g. blood cells) by the removal of supernatants.

Mycoplasma is one of the most common cell culture contaminants, with six species of mycoplasma accounting for 95% of all contamination. Therefore, it is important to improve our understanding of where mycoplasma contamination can stem from and how best to prevent it. Download this infographic to discover more about mycoplasma contamination in cell culture labs.

Here is the original post:
Meet the Culprits of Cell Culture Contamination - Technology Networks

The research dives deep into the global share, size, and trends, as well as growth rate of the Animal Stem Cell Therapy market to project its progress during the forecast period, i.e., 20202025. Most importantly, the report further identifies the past, present, and future trends that are expected to influence the development rate of the Animal Stem Cell Therapy market. The research segments the market on the basis of product type, application, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, demand and production capability across different countries.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Animal Stem Cell Therapy market.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.reportsweb.com/inquiry&RW00013146465/sample

Researchers conducting the research also carry out a comprehensive analysis of the recent amendments in the government regulation and their impact on the competitive landscape of the industry. The research assesses the recent progress in the competitive landscape including collaborations, joint ventures, product launches, acquisitions, and mergers, as well as investments in the sector for research and development.

The report profiles the key players in the industry along with a detailed analysis of their individual positions against the global landscape. The researcher provides an extensive analysis of the Animal Stem Cell Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

The major manufacturers covered in this report:

Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc, VETSTEM BIOPHARMA, Magellan Stem Cells, J-ARM, Animal Cell Therapies, Celavet Inc., VetCell Therapeutics, Animal Stem Care, Cell Therapy Sciences, Animacel, etc.

Scope of the report:

This research evaluates micro-markets and takes a closer look at the different growth trends, future prospects and regulations that will regulate the industry in the coming years. Researchers have also included a few top performers in the sector to calculate their industry shares and core competencies. The research explains technological developments in the sector along with upcoming areas of the industry that might potentially attract massive investments.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.reportsweb.com/inquiry&RW00013146465/discount

Most important Products of Animal Stem Cell Therapy covered in this report are:

Most important Application of Animal Stem Cell Therapy covered in this report are:

Scope of the study:

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsweb.com/inquiry&RW00013146465/buying

About ReportsWeb:

ReportsWeb is a one stop shop of market research reports and solutions to various companies across the world. We help our clients in their decision support system by assisting them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:

Name: Sameer JoshiEmail: [emailprotected]Phone: +1-646-491-9876

Here is the original post:
Global Animal Stem Cell Therapy Market Trends, Size, Analysis and Forecast from 2020 to 2025 - Fusion Science Academy

Global High Pressure Balloon Catheter Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global High Pressure Balloon Catheter industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2582408&source=atm

For competitor segment, the report includes global key players of High Pressure Balloon Catheter as well as some small players.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of High Pressure Balloon Catheter in these regions, from 2014 to 2025, coveringNorth America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Turkey etc.)Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)South America (Brazil etc.)Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market includeBoston ScientificMedtronicTeleflexAbbott VascularCook MedicalOlympusBDTerumoB. BraunOptimedColoplastSIS-MedicalNordson MedicalOsypka MedicalKossel Medtech (Suzhou) Co., LtdBy the product type, the market is primarily split intoPolyurethaneNylonOthers

By the end users/application, this report covers the following segmentsHospitalsClinicsOthers

We can also provide the customized separate regional or country-level reports, for the following regions:North AmericaUnited StatesCanadaMexicoAsia-PacificChinaJapanSouth KoreaIndiaAustraliaIndonesiaThailandMalaysiaPhilippinesVietnamEuropeGermanyFranceUKItalyRussiaCentral & South AmericaBrazilMiddle East & AfricaTurkeyGCC CountriesEgyptSouth Africa

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2582408&source=atm

Important Key questions answered in High Pressure Balloon Catheter market report:

What will the market growth rate, Overview, and Analysis by Type of High Pressure Balloon Catheter in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in High Pressure Balloon Catheter market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of High Pressure Balloon Catheter market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2582408&licType=S&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe High Pressure Balloon Catheter product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of High Pressure Balloon Catheter , with price, sales, revenue and global market share of High Pressure Balloon Catheter in 2019 and 2015.

Chapter 3, the High Pressure Balloon Catheter competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the High Pressure Balloon Catheter breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, High Pressure Balloon Catheter market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe High Pressure Balloon Catheter sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Go here to read the rest:
Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 - Fusion Science Academy

In 2019, the Stem Cell Therapy market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Stem Cell Therapy market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Stem Cell Therapy market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Stem Cell Therapy market research study, 2018 is considered as the base year, and 2019-2019 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

Global Stem Cell Therapy market report on the basis of market players

The report examines each Stem Cell Therapy market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Stem Cell Therapy market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Report available at a discounted price exclusively!!! Offer ends today!!!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The Stem Cell Therapy market report answers the following queries:

The Stem Cell Therapy market report provides the below-mentioned information:

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Research Methodology of Stem Cell Therapy Market Report

The global Stem Cell Therapy market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Stem Cell Therapy market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Stem Cell Therapy market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Read more:
Soaring Demand for Clean-label Food Products to Trigger the Growth of the Stem Cell Therapy Market 2017 2025 - Fusion Science Academy

Stafford Township, NJ Stem cell therapy is an incredible process for healing damaged tissue, so it seems remarkable that it is availablefor petsright here in Manahawkin. Stafford Veterinary Hospital, at 211 North Main St., began offering the advanced treatment in 2019, under the direction of Michael Pride, medical director at the facility.

There, stem cell therapy is most commonly applied to osteoarthritis, but can also be used in dogs suffering from hip dysplasia and ligament and cartilage injuries, as well as mobility ailments and some chronic inflammatory issues such as inflammatory bowel disease and chronic kidney disease, which is common in cats.

Stem cell therapy is actually the only thing that can help to reverse the process of arthritis, Pride said. Everything else is a Band-Aid.

This process can actually help to rebuild cartilage and really reduce inflammation without the need of using aspirin-type medications, Pride said. Its a newer technology that we can use to avoid chronic use of medications, which might actually be detrimental in the long term for the liver or kidneys.

Stem cell therapy treats the source of the problem by offering the ability to replace damaged cells with new ones, instructs the website staffordvet.com.

Stem cells are powerful healing cells in the pets body that can become other types of cells. For example, in the case of arthritis, stem cells can become new cartilage cells and have natural anti-inflammatory properties, thus reducing pain and increasing mobility.

The stem cells are your primary structural cell for all other cells in the body; they can differentiate into almost any other cell, explained Pride. Were processing it down into that primordial stem cell; were activating it, and were injecting it into where it needs to be, and it just starts taking on the characteristics of the cells around it.

Table-top machines from MediVet Biologics are the first Adipose Stem Cell therapy kits for in-clinic use, a major advancement. Stem cell therapy for animals has been commercially available since 2004. MediVet pioneered in-clinic treatment options around 2010.

Pride believes Stafford Veterinary Hospital offers the only such treatment in the immediate area; another is in Egg Harbor Township, Atlantic County.

Were always trying to figure out different ways to help the patient without hurting them, he said while petting a kitten that had been a patient for another type of treatment.

As stem cell therapy is more in the news regarding humans, a pet owners first question might be where the stem cells come from that are used in the process. The answer: from fat tissue of the pet itself, extracted and processed the same day.

As the therapy has been refined in the last decade, it has actually started to become a lot easier, more cost-effective more recently, said Pride, since weve been able to process fat tissue instead of actually getting bone marrow.

Fat tissue actually has a much higher concentration of adult stem cells than bone marrow does, so its less painful for the patient, they heal a lot easier, and we dont have to process it in a different facility.

Everything comes from the animal, and we give it back to the animal. Nothing comes from another animal. We dont have to worry about them rejecting the sample; its their own tissue, and were giving it back to them.

The pet typically goes home the same day after about eight hours. First, X-rays and a consultation with the veterinarian can determine whether the pet is a candidate for the treatment.

A pet owner may not even know that their animal has arthritis.

Cats have a lot of inflammatory issues that they tend to be very good at hiding, said Pride. A lot of people dont realize that they have arthritis. They think, oh, my cats just getting older; hes not jumping as much; hes not as strong; hes just sleeping most of the day, but actually he has arthritis. Its very difficult to diagnose in cats. A lot of times you end up having to do X-rays to find where the arthritic joints happen to be.

An inch-and-a-half incision is the minor surgery that harvests the fat tissue from the belly while the pet is anesthetized. For a cat, about 20 gramsare extracted. For a large dog, about 40 gramsare needed. While the pet is recovering from the incision surgery, the veterinary hospital is processing the sample. When the sample is ready, the pet is sedated because we then have to give them the joint injections. Then we can reverse the sedation, and they go home.

We asked the doctor if the process always works. He gave the example that on average, a dog such as a boxer that was hobbled is now able to walk without seeming like its painful. In an extreme positive case, a dog that had been barely walking might be bouncing all over the place in two months.

It doesnt always work to the extent that we would love it to, but we usually notice that there is a positive effect from it, Pride remarked. Every patient will be different in what they experience.

For the same reason that everyones situation is going to be different, cost of treatment was not given for this story.

It generally takes about 30 to 60 days for relief to show, the veterinarian said, and the animals progress will be monitored.

On average, results last about 18 months to two years before more stem cells might have to be injected. The procedure takes about an hour.

The nice thing is once we collect those stem cells (from the first procedure), we can bank the leftovers they are cryogenically stored at MediVet corporate headquarters in Kentucky and we dont have to go through the initial anesthetic surgery, said Pride.

Stem cell therapy is one of several innovative modalities available at Stafford Veterinary Hospital. Laser therapy, acupuncture and holistic medicine are others. Care for exotic pets is available, as is emergency pet care.

Visit the website staffordvet.com or call 609-597-7571 for more information on general and specialized services, including: vaccinations, microchipping, spayingand neutering, dental care, wellness exams, dermatology, gastrology, oncology, opthalmology, cardiology, soft-tissue surgery, ultrasound, radiography, nutrition, parasite control, boarding, laborand delivery, end-of-life care, and cremation.

Stafford Veterinary Hospital has been in business since 1965, founded by Dr. John Hauge. Today, five highly skilled veterinarians are on staff, and a satellite, Tuckerton Veterinary Clinic, is at 500 North Green St. in Tuckerton.

Pride has been medical director at Stafford Veterinary Hospital since 2008. He attended Rutgers University, then earned his Veterinary of Medicine degree at Oklahoma State University.

The mild-mannered doctor feels a great rewardfrom treating animals that cant speak for themselves when they feel bad.

These guys, theyre always thankful; you can see what they think, he said of treated pets. The turnaround in their attitude, the turnaround in their ability to be more comfortable, you can see it in their faces; you can see it in their actions. You learn to read animals over time.

Its knowing that were helping those who cant help themselves, he added, and you can see it in them; thats the most gratifying.

mariascandale@thesandpaper.net

Read this article:
Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital - By MARIA SCANDALE - The SandPaper

STATN ISLAND, N.Y. -- As a Manhattan-based attorney, Chris Cardillo has overseen his share of medical management over the years.

Paperwork involved with being a doctor is so overwhelming these days, he said, noting that many physicians turn to attorneys to help manage their practices.

So with a wide knowledge of the medical industry, he sought to open a business that would house different physicians, as well as spa services, in a medical spa setting under one roof.

The result is NVY Center, a medical management company that opened in Richmond Valley more than one year ago.

As a Manhattan-based attorney, Chris Cardillo has completed his share of medical management over the years. Paperwork involved with being a doctor is so overwhelming these days, he said, noting that many physicians turn to attorneys to help manage their practices. (Staten Island Advance/Tracey Porpora)

I became very interested in the concept because I think its the wave of the future, said Cardillo, who has several partners in the business. Almost every medical office has a medical manager. ...When you go to a hospital, like New York University Medical Center, the hospital does all the management for doctors with affiliated practices. What hospitals do for their doctors, we do on a private level.

MEDICAL, SPA SERVICES UNDER ONE ROOF

NVY Center rents a clean, white expansive space to various medical professionals, and aestheticians, who provide spa services.

We are hoping to be a national brand. What we do is solicit doctors to lease space for us and we manage them. That means when a doctor comes in here the only thing the doctor has to worry about is taking care of the patient, said Cardillo. We take care of the billing. They dont have to do any of the paperwork. Everything they need to do their job is here for them already.

Under the NVY Center roof are an array of spa services -- from stem cell therapy and IV drips to facials and aesthetic injections. (Staten Island Advance/Tracey Porpora)

MEDICAL SPA SERVICES

Under the NVY Center roof are also an array of medical spa services, from stem cell therapy and IV drips, to facials and aesthetic injections.

Included in the facilitys design are individual medical offices, rooms where different procedures, such as facials, can take place, and an IV drip chair area. And the facility always has a medical professional on the premises, said Cardillo.

We do everything from anti-hangover to anti-flu drip. ... Soon, well be able to come to your house and do an IV drip, explained Cardillo. We want this to be a one-stop-shop for modern services."

He noted the IV drips often include vitamins and are used for various purposes, including by those people who desire to lose weight.

We have fast-drips that are 15 minutes long, where we can fill you with fluids if youre not feeling good, said Cardillo. Depending on what were trying to treat, we will mix vitamins and other medicines into the IV drip. But the fluid helps no matter what.

He said the company also hosts IV drip and Botox parties.

Other services include Trusculpting," a fat reduction procedure to lose weight, and laser hair removal, said Cardillo.

NVY CENTER AT A GLANCE

Address: 236 Richmond Valley Rd.

Website: http://www.nvycenter.com

Facebook: http://www.facebook.com/nvycenter/

New Businesses in Focus is a weekly column that relates the stories of new Staten Island businesses owners.

If you have a new business on Staten Island, e-mail porpora@siadvance.com.

MORE NEW BUSINESSES IN FOCUS COLUMNS:

FOLLOW TRACEY PORPORA ON FACEBOOK and TWITTER

Here is the original post:
Botox, medical drips and more offered at NVY Center - SILive.com

NEW YORK, Jan. 13, 2020 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium"), announced today that it has entered into an agreement with the University of California, Davis (UC Davis) to utilize Actinium's Antibody Radiation-Conjugate or ARC apamistamab-I-131 for targeted conditioning and replace the chemotherapy conditioning being used in an ongoing Phase 1/2 stem cell gene therapy clinical trial. In the trial, patients with relapsed or refractory HIV-related lymphoma are being treated with autologous stem cell gene therapy. This is the first gene therapy clinical trial that will utilize ARC based conditioning. The clinical trial will be conducted at UC Davis and may be expanded to additional sites in the future.

Dr. Mehrdad Abedi, Professor, Hematology and Oncology at UC Davis and study lead, said, "This collaboration represents an exciting combination of revolutionary technologies that could further our ability to treat patients with HIV and other life-threatening diseases with gene therapy. Despite the advances made in the field of gene therapy, the reliance on non-targeted chemotherapy and external radiation as conditioning regimens is less than optimal and poses a problem that we hope to reduce or eliminate as part of this collaboration by replacing our conditioning regimen in this study with Actinium's ARC based targeted conditioning. Advances in HIV therapies have dramatically improved patient survival, but current therapies require life-long daily use to keep the HIV virus at bay, can have severe side effects, may be overcome by HIV resistance and do not address the needs of all patients like those in this study with HIV-related lymphomas. We envision a future where a single treatment of our stem cell gene therapy can cure patients of their lymphoma and HIV leaving the patient with a new immune system that can fight, be resistant to and prevent the mutation of HIV. Apamistamab-I-131's demonstrated antitumor effect against lymphoma and ability to condition patients in a targeted manner with a demonstrated tolerable safety profile in the bone marrow transplant setting makes it an ideal conditioning agent for this patient population. Based on these factors and extensive supporting clinical data in the Iomab-B program, we selected this ARC as the conditioning agent for the next phase of our trial as we believe antibody radiation-conjugates are more advanced and hold distinct advantages over novel but unproven conditioning technologies such as Antibody Drug Conjugates and naked antibodies that are beginning to be developed albeit at the preclinical stage."

In the current clinical trial, the anti-HIV stem cell gene therapy is produced by taking a patient's own or autologous, blood forming stem cells and genetically modifying them via gene therapy with a combination of three anti-HIV genes. The intended result is for the gene modified bone marrow stem cells to produce a new immune system and newly arising immune cells that are resistant to HIV via a single treatment. Conditioning is necessary prior to adoptive cell therapies such as gene therapy to eliminate certain cell types such as immune cells and stem cells in the bone marrow so the transplanted cells can engraft. Until now, conditioning in this trial, as is typical, used a multi-drug chemotherapy regimen administered over several days. This approach is non-targeted, associated with toxicities that impairs patients and restricts the use and efficacy of cellular therapy. Apamistamab-I-131, which requires just one therapeutic administration, will displace the non-targeted chemotherapy to condition patients in a targeted manner with the goal of reducing conditioning related toxicities and improving patient outcomes. Actinium and UC David will cross-reference their respective Investigational New Drug applications and will work collaboratively to obtain necessary regulatory and institutional approvals. In this clinical collaboration, Actinium will provide drug product, support for its administration and certain trial costs. UC Davis will be responsible for the production of the anti-HIV stem cell gene therapy and overall conduct of the study and its cost.

Dr. Dale Ludwig, Actinium's Chief Scientific Officer, said, "We are excited to be working with Dr. Abedi on this clinical study and we appreciate his recognition of the value of our Iomab-ACT targeted conditioning program may provide in support of gene stem cell therapy. This targeted approach using our CD45 ARC, enables both anti-tumor activity and effective conditioning with the potential for reduced toxicity compared to non-targeted chemotherapy and external radiation in the bone marrow transplant setting. Supported by extensive clinical investigation in 12 trials and over 300 patients, a single therapeutic dose of apamistamab-I-131 is sufficient for conditioning and, due to its dual activity, even a patient with active disease could expect to receive therapy within two weeks, which is anticipated to lead to better outcomes compared to chemotherapy, external beam radiation, or exploratory approaches such as naked antibodies or Antibody Drug Conjugates. In addition, CD45, the target of apamistamab-I-131, is ideal for targeted conditioning, as it is not expressed outside of the haemopoietic system and, because it is a poorly internalizing receptor. An ARC approach which does not require internalization of its radionuclide warhead for target cell killing, is anticipated to be more viable and more effective than Antibody Drug Conjugate approaches which need to internalize their payloads. Given the potential of this ARC targeted conditioning technology for bone marrow transplant, we are grateful to Dr. Abedi for the opportunity to advance the Iomab-ACT program into the promising field of gene stem cell therapy."

Sandesh Seth, Actinium's Chairman and Chief Executive Officer, said, "Actinium is thrilled to be working with UC Davis and honored to now be part of this important trial. It has become evident that better conditioning regimens are needed for cell and gene therapies to reach their full potential. Our team is proud to be the first company to establish a clinical stage targeted conditioning portfolio for both cell and gene therapy. We are pleased to extend our ARC technology for targeted conditioning into these rapidly advancing fields and we are committed to establishing a strong leadership position in enabling these adoptive cell therapies fully realize their great potential for improving patients' lives."

Apamistamab-I-131's demonstrated conditioning and antitumor effect in lymphoma1

Actinium's apamistamab-I-131 ARC has been studied as a targeted conditioning agent in over 300 patients in the bone marrow transplant setting in the Iomab-B Program and is currently being studied in a pivotal Phase 3 clinical (SIERRA) trial in patients with relapsed or refractory acute myeloid leukemia. Clinical proof of concept has been established with Iomab-B for targeted conditioning in high-risk, relapsed or refractory lymphoma patients prior to an autologous stem cell transplant where a favorable safety profile with no dose limiting toxicities and minimal non-hematologic toxicities observed and promising efficacy with median overall survival not reached (range: 29 months to infinity) and 31% of patients in prolonged remission at a median of 36 months follow up (range: 25 41 months)1.

1) Cassaday et al. Phase I Study of a CD45-Targeted AntibodyRadionuclide Conjugate for High-Risk Lymphoma. AACR Clin Cancer Res Published OnlineFirst September 3, 2019

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, apamistamab-I-131 (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and promising single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. Apatmistamamb-I-131 will also be studied as a targeted conditioning agent in a Phase 1/2 anti-HIV stem cell gene therapy with UC Davis and is expected to be studied with a CAR-T therapy in 2020. In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors:Hans VitzthumLifeSci Advisors, LLCHans@LifeSciAdvisors.com(617) 535-7743

Media:Alisa Steinberg, Director, IR & Corp Commsasteinberg@actiniumpharma.com(646) 237-4087

SOURCE Actinium Pharmaceuticals, Inc.

http://www.actiniumpharma.com/

Excerpt from:
Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related...

Global Musculoskeletal Disorder Stem Cell Therapy Market Growth (Status and Outlook) 2019-2024 Overview :

According to this study, over the next five years the Musculoskeletal Disorder Stem Cell Therapy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024

A newly revealed market research study titledGlobal Musculoskeletal Disorder Stem Cell Therapy MarketbyMRInsights.biz, studies market insights, list of significant key professionals, threats of new competitors and alternate products. The report presents in-depth analysis along with competitive insights, segmentation, and the market size information. In addition, it exploresMusculoskeletal Disorder Stem Cell Therapymarket size, trends, share, growth, development plans, growth opportunity, cost structure and drivers analysis.One part of this report contains production in which analysis on the production, revenue, gross margin of its main manufacturers in different regions from 2014 to 2019 has been covered. It also makes a prediction of its production and consumption in coming 2019-2024. The report provides a detailed analysis by the categorization of the global market on the basis of regions.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/177475/request-sample

Globally top leading manufacturers listed here: Osiris Therapeutics, NuVasive, Takeda (TiGenix), Medi-post,

Market region segmentation:

Furthermore, the SWOT analysis and strategies of each vendor are highlighted in the report which can be employed to create future opportunities.It sheds light on its applications, types, deployments, components, growths of this market. The research has also carried out analysis on upstream raw materials, equipment and downstream consumers. Next, it analyzes volume, utilization value, sale price, import and export in different regions from 2014 to 2019. On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, while for end use/application segment, this report focuses on the status and outlook for key applications.

The GlobalMusculoskeletal Disorder Stem Cell TherapyMarket Report Contains:

Next, the raw data collected through several sources has been processed using various mathematical and analytical tools and techniques in order to conclude the significant information related to future growth prediction trend for 2019 to 2024 time frame. At the end, research findings and conclusions specified in the report will help decision makers to take vital choices in the near future.

READ FULL REPORT:https://www.mrinsights.biz/report/global-musculoskeletal-disorder-stem-cell-therapy-market-growth-177475.html

There are 12 Chapters to deeply display the globalMusculoskeletal Disorder Stem Cell Therapymarket.

Chapter 1:Scope of the Report

Chapter 2:Executive Summary

Chapter 3:GlobalMusculoskeletal Disorder Stem Cell Therapyby Manufacturers

Chapter 4:Musculoskeletal Disorder Stem Cell Therapyby Regions

Chapter 5, 6, 7, 8 and 9:Americas,APAC,Europe,Middle East & Africa,Market Drivers, Challenges and Trends

Chapter 10 and 11:GlobalMusculoskeletal Disorder Stem Cell TherapyMarket Forecast,Key Players Analysis

Chapter 12 :Research Findings and Conclusion.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Read this article:
Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 2024 Qualitative and Quantitative Assessment by Industry Analysis across the Value...

CONWAY, Ark. A Conway man has spent many years living with Multiple Sclerosis, but this year he was also diagnosed with ALS, or Lou Gherigs Disease.

For the Nobles family, every day with their father, Greg, is a treasured moment.

"I was first diagnosed 16 years ago with MS," said Greg Nobles.

Life has been a challenge since, but it was this January when his health began to decline severely.

Greg lost all mobility. After getting treated for his symptoms and not seeing a difference is when neurologists confirmed Greg also suffers from ALS, a nervous system disease weakening muscles with no cure.

"Doctors have never seen a patient with both before, said Bailey Smith, Gregs daughter. Being diagnosed MS first, we got 15 good years with him versus the ALS now.

RELATED: A final fundraiser for the man who boosted the ice bucket challenge

Once active and known as one of the best hairstylist in town, Gregs now homebound hoping for relief from the pain he endures.

"My husband passed away from ALS in 2004, so I know the journey they are going on, said Diana Kirkland, a hair client of Gregs.

Kirkland knew she needed to do something for the Nobles.

She owns Legacy Acres in Conway.

This week shes preparing her space for a fundraising event Friday night to raise money so Greg can receive stem cell therapy, an expensive procedure done in Mexico, but one that will reduce his discomfort.

"If I could just get some mobility back, it's worth it, said Greg.

Greg has already received two rounds of stem cell therapy.

RELATED: Arkansas man raises money for charity by streaming 24-hour gaming session

Fortunately, hes starting to notice relief in his left leg.

But with ALS, hes given 3 to 5 years to live, but with a community coming together to help, his family hopes that love and support will give them more time with him.

"It means everything to us, said Smith. To continue to get stem cells for us, my babies to see my dad keep fighting.

Greg Nobles Fundraising Dinner is at Legacy Acres, 100 Legacy Acres Drive, in Conway on Friday night beginning at 6 p.m.

Everyone is invited. The event will have live music, a silent auction, catered food provided by Catering By S and I.

There will also be a donation table set up for a stem cell therapy fund.

Here is the original post:
Conway supports man fighting rare double diagnosis of MS, ALS - THV11.com KTHV

Growth of Global Stem Cell Therapy Market Size is favored by cumulative factors like development of advanced genome-based cell analysis techniques, soaring awareness of the therapeutic potency of stem cells, detection of novel stem cell lines, and developments in infrastructure related to stem cell banking and processing, and increasing public-private investments for development of stem cell therapies.

In the upcoming years, North America is likely to dominate the global stem cell therapy market share. The U.S. dominates the market which is followed by Canada. Stem cell therapy is powered to cure diseases like diabetes and cancer. There is an increase in occurence of such diseases and higher awareness for the treatment of such diseases is propelling stem cell therapy market. New product innovation & launching, increase in a number of clinical trials for evaluation of the therapeutic potential and higher adoption of these therapies & procedures is fueling market growth. Presence of numerous centers and organization that are engaged in R&D related to new stem cell therapy is likely to led lucrative market growth.

Get more insights at:Global Stem Cell Therapy Market 2020-2025

Europe holds second position in the lucrative market of stem cell therapy. This is attributed to development of efficient & advanced technologies and growing investment in healthcare industry.

The Asia Pacific is projected to exhibit the highest growth in the market. The key countries that are expected to experience fastest development are India and China. The higher adoption of grants by several funding agencies and government for scientific researches is anticipated to stimulate the regional market growth. Investment of leading players for launch and development of newer technologies and increase in healthcare expenditure are also anticipated to up surge the Asia-Pacific market growth of stem cell therapy.

The Middle East & Africa and Latin America regions are expected to show slow growth in the forecast period. Rising awareness about the SC therapies, growing expenditure in the healthcare sector, rapid development in the infrastructure of healthcare and adoption of western technologies and lifestyle is expected to fuel the growth of the stem cell therapy market.

In terms of types of global stem cell therapy market is bifurcated into autologous stem cell therapy and allogeneic stem cell therapy. The segment of allogeneic stem cell therapy is likely to command largest global stem cell therapy market share. This is attributed to easy production scale-up process, escalating commercialization of allogeneic stem cell therapy products, the extensive therapeutic applications of allogeneic stem cells and mounting number of clinical trials related to allogeneic stem cell therapies.

Based on therapeutic application, the global stem cell therapy industry has wide range of categories which includes musculoskeletal disorders, cardiovascular diseases, gastrointestinal diseases, wounds and injuries, surgeries, and other applications. The musculoskeletal disorders sector is anticipated to dominate the global stem cell therapy market by holding largest share. This is attributed to the high prevalence of bone & joint diseases, musculoskeletal disorders, escalating availability of stem cell-based products for the treatment of musculoskeletal disorders and higher patient preference for effective & early treatment strategies.

Get more details about Global Stem Cell Therapy Market:

https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

The global stem cell therapy market is niche industry with soaring global and local companies involved in the commercialization and development of stem cell therapy products. Anterogen Co., Ltd. (South Korea), MEDIPOST Co., Ltd. (South Korea), Osiris Therapeutics, Inc. (U.S.) and Pharmicell Co., Ltd. (South Korea) are the prominent market players of the global stem cell therapy market. The major strategies adopted by leading market players include expansions, partnerships, new product launches and approvals, and agreements to achieve growth in the global stem cell therapy market.

Key segments of Global Stem Cell Therapy Market

Based on cell source, the market has been segmented into,

Based on therapeutic application, the market has been segmented into,

Based on region, the market has been segmented into,

What to expect from the upcoming report on Global Stem Cell Therapy Market:

Future prospects and current trends of the global stem cell therapy market by the end of forecast period (2018-2025)

Information regarding technological progressions as well as innovations taking place in developing economies

Supportive initiatives by government likely to influence the market dynamics

Trends, drivers, opportunities, restraints, challenges and key developments in the market

In-depth analysis of different market segmentations including regional segmentations, and product types

Deep analysis about the competitive landscape of the market and the initiatives by them to improve this market

For Any Query on the Stem Cell Therapy Market:

https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About US:

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX 75204, U.S.A

Phone No.: USA: +1 972-362 -8199 / +91 9665341414

This post was originally published on The Picayune Current

Originally posted here:
Stem Cell Therapy Market 2020 Analysis by Treatment, Application, Technology, Therapy With Regional Outlook & Forecast To 2025 - The Picayune...

Dublin, Dec. 31, 2019 (GLOBE NEWSWIRE) -- The "Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The stroke therapeutics market analysis considers sales from both ischemic stroke and hemorrhagic stroke types. The analysis also considers the sales of stroke therapeutics in Asia, Europe, North America, and ROW. In 2018, the ischemic stroke therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as availability of patient assistance programs will play a significant role in the ischemic stroke therapeutics segment to maintain its market position. Also, the global stroke therapeutics market report looks at factors such as high-risk factors for stroke, strong pipeline, and growth of the geriatric population. However, high level of genericization in the market, availability of substitutes, and clinical trial failures may hamper the growth of the stroke therapeutics industry over the forecast period.

Globally, stroke is the second-leading cause of death among adults. The high prevalence of stroke is attributed to the increase in the incidence of ischemic strokes and hemorrhagic strokes, mainly because of the increasing presence of high-risk factors over the years. The major risk factors such as high blood pressure, high cholesterol levels and obesity, heart diseases, and diabetes are increasing the number of strokes that results in several deaths across the world. The risk of stroke also increases due to excessive smoking and alcohol consumption. Such risk factors will lead to the expansion of the global stroke therapeutics market at a CAGR of almost 5% during the forecast period.

The global stroke therapeutics market is expected to benefit from the development of novel therapies, such as stem cell therapies. Owing to the high prevalence of stroke, there is a huge need for safe and innovative novel therapies to treat stroke. Therefore, several companies are developing novel drugs for the treatment of stroke. The development of stem cell therapy will have a major impact on upcoming stroke therapeutics, as it has fewer side effects and regenerative properties. Some of the other novel drugs currently under various stages of development in the stroke therapeutics market are PSD-95 antagonist NA-1 developed by NoNO and 3K3A-APC developed by ZZ Biotech LLC. Such development of novel therapies with fewer side effects is expected to have a positive impact on the overall market growth.

With the presence of several major players, the global stroke therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading stroke therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.

Also, the stroke therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPEPART 04: MARKET SIZINGPART 05: FIVE FORCES ANALYSISPART 06: MARKET SEGMENTATION BY TYPE

PART 07: CUSTOMER LANDSCAPEPART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORKPART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDSPART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/af16zt

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023 - GlobeNewswire

The 2010s are coming to an end, and looking back there have been some pretty amazing advances and innovations in health and science.

Advances in prosthetic limbs

Prosthetic limbs have been around since ancient times. In Egypt, a prosthetic wooden toe was found on a mummy dating back 3,000 years. By the Dark Ages, inventors could incorporate hinges on prosthetic arms used by knights. In modern times, the field of prosthetics has turned to incorporating more technology into physical stand-ins for limbs. In the last several years, theres been a boom in advances that have led to the best and most useful prosthetics weve ever seen.

Reports from the early 2010s talked about the potential for new technology to allow people to control prosthetics with their minds and to receive sensory information from their devices. It may have been a reach in the early part of the decade, but now it is literally within grasp. There are new prosthetic hands being tested that give the user the ability to grab objects with their thoughts and even to sense the texture of what they are touching. New bionic hands allow the user to feel again by sending signals back to the brain about the things they are touching, like whether its hard or soft. Other research groups have been working on bionic arms that can move based on the users thoughts through a brain-computer interface. While these have demonstrated its possible to accomplish these goals in the lab, theres still more to be done before people can use these devices outside in the real world.

Many of these advanced prosthetics are still prototypes and may not reach the general population for a while. Luckily, cheaper 3D printers have made simple prosthetics more accessible. These are important because a prosthetic device can improve the quality of life for people. For example, this person has been printing prosthetic hands and arms for people in Africa after watching an online tutorial. New materials that go into 3D printers are cheaper than they used to be and are being used in prosthetics to provide a more affordable option for patients.

Although prosthetics have been around for ages in some form or another, they arent always used. One variable to consider is the social acceptance of having a prosthetic. Theres still a lot of stigma around disabilities and many people may reject prosthetics even if they are available. In 2012, an athlete with both feet amputated competed in the mens 400 meter race at the Olympics in London. There was some controversy over whether the runner with a prosthetic foot should be allowed to run in races with people who dont have prosthetics or if they should only be allowed in competitions specifically for people who have them. Prosthetics also need to be comfortable and usable in order to be successfully adopted. In one study, about 4.5 percent of people rejected prosthetics and 13.4 percent stopped using their prosthetics. As the new prosthetics that are more natural and intuitive to use come to market, hopefully more people will benefit, and the social barriers to acceptance will disappear.

CRISPR

The genome modification technique called Clustered Regularly Interspaced Short Palindromic Repeats, aka CRISPR, was a culmination of a few decades of work by scientists, and major studies explaining the method were published in 2013. The version of it called CRISPR-associated protein 9 or CRIPSR-Cas9 is what most researchers are specifically using in most cases. It involves a regular gene editing mechanism that happens in bacteria. The bacteria can take sections of DNA from attacking viruses and essentially use that to remember the viruses if they return. When the virus is back, the bacteria can target the matching sections of DNA in the virus, cut it and disable the virus.

Though 2013 was only six years ago, as far as science goes, CRISPR has been moving at lightning speed towards practical applications. Using CRISPR to edit a gene sequence, researchers can now add, delete or modify DNA segments more quickly and accurately than ever before. Since the technique was developed, researchers have used CRISPR to target diseases caused by a single gene like cystic fibrosis or sickle cell disease.

Probably the most infamous use of CRISPR are the CRISPR babies. In late 2018, a Chinese researcher, He Jiankui, claimed to have used CRISPR to modify the genomes of two babies to include a mutated version of a gene that protects against HIV. This case was and is highly controversial for the ethical concerns with genetically modifying a human genome at the embryo level, or germline, meaning it can be passed down to future generations and has not been done before in humans. Recently, MIT Technology Review obtained excerpts from Hes research, and experts say that the report and data may be untrustworthy. This means it is still unclear if He and collaborators actually successfully modified the babies genomes. The scientific community overall condemns this way of using CRISPR to edit a human germline genome and has called for an international moratorium on it until a framework can be agreed on.The researcher has been sentenced to three years in prison in Shenzhen, China.

As fraught with controversy as the CRISPR babies may be, CRISPR technology still holds a lot of promise and can be used responsibly, supporters say. For example, researchers are using it to target cancer cells by taking a patients immune cells, modifying them using CRISPR and then infusing the patient with the modified cells. For blood diseases, a patient with sickle cell disease is reported to be responding well to a CRISPR treatment that has allowed her body to produce a crucial protein.

Another area that has boomed this decade partly because of CRISPR technology is stem cell therapy, which well get into in the next section.

Stem cell therapy

Technically, the only Federal Drug Administration (FDA)-approved stem cell therapies are blood-forming stem cells derived from umbilical cord blood. Blood-forming stem cells are used to treat patients with cancer after chemotherapy has depleted blood cells, as well as patients with blood disorders like leukemia whose bone marrow tissues are damaged. These types of treatments have been around for about 30 years, but in the 2010s weve seen potential for more uses of stem cells in health care.

The main idea behind stem cell therapy is that because the cells are pluripotent meaning they can become many other types of cells they can be introduced into parts of the body that are damaged and need new cells. On top of that, researchers can now extract some types of stem cells from a persons body, so no need for umbilical cords. This opens up the possibilities for highly personalized treatment where one person can be treated with stem cells from their own body.

Researchers are exploring how stem cells can be used to treat liver disease, cerebral palsy, stroke, brain injury and others. There are many ongoing research-backed clinical trials for stem cell therapy. A quick search for stem cell therapy on the governments clinical trial database turns up 5,638 results. And because of the work necessary to even get to the clinical trial stage, theres likely an order of magnitude more stem cell therapy studies in the pre-clinical trial stages.

Stem cell therapy is also being offered in for-profit clinics around the U.S. In these cases, the clinics are typically taking fat tissue from a patient, isolating the stem cells and then administering the stem cells back to the patient. In some cases, the treatments may lead to health complications, like blindness in a few extreme cases, and the FDA warns that such treatments are unapproved and potentially harmful. The FDA is ramping up regulation of stem cell clinics and earlier this year took a specific clinic in Florida to court.

Although there are many stem cell clinics offering unproven stem cell therapies, its not all hype. Granted that its difficult to pass the clinical trial stage to get FDA approval, stem cell research may lead to new treatments for several health conditions that could completely change the health care landscape.

You can follow Chia-Yi Hou on Twitter.

See the article here:
The most important health innovations of the past decade - The Hill

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues and tumors, wherein their toxicity, impurity, and other aspects are studied.

Download Brochure of This Market Report at https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

With the growing number of successful stem cell therapy treatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

The rest is here:
Stem Cell Assay Market Expected to Witness a Sustainable Growth over 2025 - Filmi Baba

Market Synopsis :-The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe.

The study on the Canine Stem Cell Therapy Market attempts to provide significant and detailed insights into the current market scenario and the emerging growth prospects. The report on Canine Stem Cell Therapy Market also emphasizes on market players as well as the new entrants in the market landscape. The expansive research will help the well-established as well as the emerging players to set up their business strategies and achieve their short-term and long-term goals. The report also adds significant details of the evaluation of the scope of the regions and where the key participants should head to find potential growth opportunities in the future.

Access PDF Sample Copy of the Report, With 30 mins free consultation! Click [emailprotected] https://garnerinsights.com/Global-Canine-Stem-Cell-Therapy-Market-Size-Status-and-Forecast-2019-2025#request-sample

The report also presents a thorough qualitative and quantitative data pertaining to the projected impact of these factors on markets future growth prospects. With the inclusive market data concerning the key elements and segments of the global Canine Stem Cell Therapymarket that can influence the growth prospects of the market, the report makes for a highly informative document.

The Canine Stem Cell TherapyMarket report displays the production, consumption, revenue, gross margin, cost, market share, CAGR, and market impacting variables of the Canine Stem Cell Therapyindustry and forecast to 2025, from 2019.

The research study is based on a combination of primary as well as secondary research. It throws light on the key factors responsible for driving and restricting market growth. Furthermore, the recent mergers and acquisition by leading players in the market have been discussed at length. Moreover, the historical information and present growth of the market have been provided in the scope of the research report. The latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the market have also been included in the study.

Global Canine Stem Cell Therapymarket competition by top manufacturers/players:VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet, .

Global Canine Stem Cell TherapyMarket Segmented by Types: Allogeneic Stem Cells, Autologous Stem cells, .

Applications analyzed in this report are: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes, .

To get this report at beneficial rates @:-https://garnerinsights.com/Global-Canine-Stem-Cell-Therapy-Market-Size-Status-and-Forecast-2019-2025#discount

The Goal Of The Report: The main goal of this research study is to provide a clear picture and a better understanding of the market for research report to the manufacturers, suppliers, and the distributors operational in it. The readers can gain a deep insight into this market from this piece of information that can enable them to formulate and develop critical strategies for the further expansion of their businesses.

Table of Contents of the study:-

Chapter 1 Overview of Canine Stem Cell Therapy Market1.1 Brief Overview of Canine Stem Cell Therapy Industry1.2 Development of Canine Stem Cell Therapy Market1.3 Status of Canine Stem Cell Therapy Market

Chapter 2 Manufacturing Technology of Canine Stem Cell Therapy Industry2.1 Development of Canine Stem Cell TherapyManufacturing Technology2.2 Analysis of Canine Stem Cell TherapyManufacturing Technology2.3 Trends of Canine Stem Cell TherapyManufacturing Technology

Chapter 3 Analysis of Global Canine Stem Cell Therapy MarketKey Manufacturers3.1.1 Company Profile3.1.2 Product Information3.1.3 2013-2019 Production Information3.1.4 Contact InformationContinue

View Full [emailprotected]:- https://garnerinsights.com/Global-Canine-Stem-Cell-Therapy-Market-Size-Status-and-Forecast-2019-2025

Besides, the report centers around the major industry participants, considering the company profiles, product portfolio and details, sales, market share and contact data. Furthermore, the Canine Stem Cell Therapy Industrygrowth trends and marketing channels have also been scrutinized.

Visit link:
Canine Stem Cell Therapy Market is Expected to Thrive at Impressive CAGR by 2025 & Top Key Players are VETSTEM BIOPHARMA, Cell Therapy Sciences,...

A research team from the University of Houston has found a way to use the stem cells found in fat and guide it to become a pacemaker-like cell, according to a new study.

We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release

The team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardia progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.

The researchers used what they called a standard screening strategy to test for reprogramming factors for converting human cardiac progenitor cells into pacemaker-like cells. According to their study results, the authors observed expressions of many pacemaker-specific genes, including CX30.2, KCNN4, HCN4, HCN3, HCN1, and SCN3b. The authors wrote that SHOX2, HCN2, and TBX5 (SHT5) combinations of transcription factors were much better candidate(s) in driving cardiac progenitor cells into pacemaker-like cells than other combinations and single transcription factors.

Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells, they wrote in their conclusion. SHT5 may be used as a potential stem cell therapy for sick sinus syndrome (SSS) and for other cardiac conduction diseases.

Original post:
The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment - DocWire News

The comprehensive report published by Persistence Market Research offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Animal Stem Cell Therapy Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Animal Stem Cell Therapy Market during the forecast period 2017 2025.

As per the findings of the presented study, the Animal Stem Cell Therapy Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Animal Stem Cell Therapy in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/14941

The report segregates the Animal Stem Cell Therapy Market into different segments to provide a detailed understanding of the various aspects of the market. The competitive analysis of the Animal Stem Cell Therapy Market includes valuable insights based on which, market players can formulate impactful growth strategies to enhance their presence in the Animal Stem Cell Therapy Market.

Key findings of the report:

The report aims to eliminate the following doubts related to the Animal Stem Cell Therapy Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/14941

Reasons to buy from PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Read the original:
Animal Stem Cell Therapy Market: Challenges and Opportunities Report 2017 2025 - Bulletin Line

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

This post was originally published on Market Research Sheets

Visit link:
Stem Cell Therapy Market Consumer Outlook 2025 | MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. - Market Research Sheets

Aspen Neuroscience, a new biotech company, has raised $6.5 million to develop cell therapies for Parkinsons disease using patients own cells.

The company was co-founded by renowned stem cell scientists Jeanne F. Loring, PhD, and Andres Bratt-Leal, PhD, and initially supported by Summit for Stem Cell, a non-profit organization that provides a variety of services for Parkinsons patients.

Parkinsons hallmark motor symptomsinclude tremor, slowness of movement (bradykinesia), stiffness (rigidity), uncontrollable movements (dyskinesia), and poor balance.

As the disease progresses, patients typically need to gradually increase their dopaminergic therapeutic dose for maximum benefit. Even after that they might sometimes experience reappearance or worsening of symptoms due to diminishing effects of dopaminergic therapy, known was off periods.

Importantly, dopaminergic therapy is delivered to areas of the brain other than the striatum, a key motor control region severely affected in Parkinsons disease. Because of the therapys off-target behavior, patients also may experience side effects such as hallucinations or cognitive impairment.

Aspen wants to combine its expertise in stem cell biology, genomics and neurology and develop the first autologous (self) stem cell-based therapy for Parkinsons disease.

In this type of cell therapy, a patients own cells (usually skin cells) are reprogrammed back into a stem cell-like state, which allows the development of an unlimited source of almost any type of human cell needed, including dopamine-producing neurons, which are those mainly affected by this disorder.

Because these cells are derived from patients, they do not carry the risk of being rejected once re-implanted, eliminating the need for immunosuppressive complementary therapies, which carry serious side effects such as infections and possibly limiting therapeutic potential.

In theory, replacing lost dopaminergic neurons with new stem cell-derived dopamine-producing ones could potentially ease or reverse motor symptoms associated with the disease.

Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinsons disease, Howard J. Federoff, MD, PhD, Aspens CEO, said in a press release.

We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist, Federoff said.

The companys lead product (ANPD001) is undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinsons disease. Aspen experts also are developing a gene-editing treatment (ANPD002) for familial forms of Parkinsons, starting with the most common genetic variant in the GBAgene, which provides instructions to make the enzyme beta-glucocerebrosidase.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32, according to the press release.

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

The rest is here:
Aspen Neuroscience Receives $6.5M for Parkinson's Stem Cell Therapy - Parkinson's News Today

Liming Wang,1,* Shigao Huang,2,* Shimei Li,1 Ming Li,1 Jun Shi,1 Wen Bai,1 Qianyun Wang,1 Libo Zheng,3 Yongjun Liu3

1Cell Therapy Center, 986 Hospital of Peoples Liberation Army Air Force, Xian, Shaanxi, Peoples Republic of China; 2Cancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, Peoples Republic of China; 3Stem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, Beijing, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Shigao HuangCancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Room 3013, Building N-22, Taipa, Macau, Peoples Republic of ChinaEmail huangshigao2010@aliyun.comYongjun LiuStem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, No. 35, Jinghai 3 Road Economic-Technological Development Area, Beijing, Peoples Republic of ChinaEmail andyliuliu2001@aliyun.com

Background: The traditional anti-inflammation disease-modifying anti-rheumatic drugs (DMARDs) have limited therapeutic effects in rheumatoid arthritis (RA) patients. We previously reported the safety and efficacy of umbilical cord mesenchymal stem cell (UC-MSC) treatment in RA patients that were observed for up to 8 months after UC-MSC infusion. The aim of this study is to assess the long-term efficacy and safety of UC-MSC along with DMARDs for the treatment of RA.Methods: 64 RA patients aged 1864 years were recruited in the study. During the treatment, patients were treated with 40 mL UC-MSC suspension product (2 107 cells/20 mL) via intravenous injection immediately after the infusion of 100 mL saline. The serological markers tests were used to assess safety and the 28-joint disease activity score (DAS28) and the Health Assessment Questionnaire (HAQ) to assess efficacy.Results: 1 year and 3 years after UC-MSC cells treatment, the blood routine, liver and kidney function and immunoglobulin examination showed no abnormalities, which were all in the normal range. The ESR, CRP, RF of 1 year and 3 years after treatment and anti-CCP of 3 years after treatment were detected to be lower than that of pretreatment, which showed significant change (P < 0.05). Health index (HAQ) and joint function index (DAS28) decreased 1 year and 3 years after treatment than before treatment (P < 0.05).Conclusion: UC-MSC cells plus DMARDs therapy can be a safe, effective and feasible therapeutic option for RA patients.

Keywords: rheumatoid arthritis, umbilical cord mesenchymal stem cell, cell therapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Visit link:
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy fo | DDDT - Dove Medical Press